CP and COVID-19: Recently, survival benefit was observed for patients with COVID-19 and immunodeficiency treated with hyperimmune anti-SARS-CoV-2 IVIGs (hCoV-2IG).4 The postinfection hCoV-2IG (pi-hCoV-2IG) lots manufactured from pooled plasma units of convalescent individuals contain immunoglobin G at 10-fold higher concentration than in CP.